George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.60
Ask: 3.70
Change: -0.10 (-2.67%)
Spread: 0.10 (2.778%)
Open: 3.75
High: 3.75
Low: 3.65
Prev. Close: 3.75
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

Tue, 06th Feb 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Beeks Financial Cloud Group PLC, up 34% at 145.00 pence, 12-month range 81.42p-155.00p. The cloud computing and connectivity provider says it has won a number of competitive tenders in the first half of financial 2024, and now expects trading in financial 2025 to be "significantly" ahead of previous board expectations. Beeks notes that it has signed a USD2.3 million Proximity Cloud expansion contract, as well as a conditional contract with "one of the largest exchange groups globally." Chief Executive Gordon McArthur says: "We continue to progress with the execution of our 'land and expand' strategy, quickly demonstrating the value of our offerings, as evidenced by the significant Proximity Cloud expansion contract announced this morning and the winning of a third major global exchange customer for our Exchange Cloud offering. We see considerable expansion potential across our customers, as they migrate increasing proportions of their trading infrastructure to the cloud."

----------

Fusion Antibodies PLC, up 16% at 5.50p, 12-month range 3.02p-56.00p. Shares in the contract researcher rise. It receives a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company". The follow on project is worth USD650,000. CEO Adrian Kinkaid says: "It is always thrilling and satisfying to share in our clients' successes. We are delighted that the programme has been so productive, and we look forward to continuing to work with our client to bring better antibodies to the clinic more rapidly. The collaborative nature of the project, with creative problem solving from both parties over the full length of the programme, makes this a model example of Fusion's Integrated Therapeutic Antibody Service and highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies."

----------

AIM - LOSERS

----------

PCI-PAL PLC, down 10% at 49.98p, 12-month range 38.25p-66.70p. Shares in the provider of cloud-based secure payment solutions for business communications fall despite a positive trading update. Revenue in the six months to December 31 rises 20% to GBP8.7 million from GBP7.3 million a year before. Annual recurring revenue in the period increases 23% to GBP14.7 million from GBP11.9 million. Looking ahead, CEO James Barham says: "The start of H2 has seen the group maintain new sales momentum and we continue to focus on delivering the group's profitability objectives, enhancing shareholder value, and capitalising on the strategic opportunities for continued growth."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Apr 2024 13:29

Fusion Antibodies inks commercial contract for OptiPhage library

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species.

Read more
27 Feb 2024 14:18

TRADING UPDATES: Sondrel wins USD23 million contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.

Read more
14 Feb 2024 12:52

Fusion Antibodies raises £1.38m as it seeks new customers

(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.

Read more
14 Feb 2024 11:27

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.

Read more
6 Feb 2024 11:48

Fusion Antibodies strikes follow-on research and development project

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".

Read more
1 Feb 2024 16:27

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.

Read more
1 Feb 2024 12:00

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

Read more
4 Dec 2023 16:56

LONDON MARKET CLOSE: FTSE 100 slips as miners hold down index

(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.

Read more
4 Dec 2023 12:01

Fusion Antibodies revenue falls, losses widen in first half

(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.

Read more
4 Dec 2023 10:23

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
4 Dec 2023 10:22

Fusion Antibodies shares fall with revenue despite "positive" outlook

(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".

Read more
28 Nov 2023 12:09

Fusion Antibodies shares up on deal with US National Cancer Institute

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.

Read more
28 Nov 2023 10:33

AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.